Dapagliflozin in the therapy of chronic heart failure of functional class II–III with moderately reduced ejection fraction
- Авторлар: Zaporozhskaya N.1, Kartashova E.1, Zheleznyak E.1
-
Мекемелер:
- Rostov State Medical University, Ministry of Health of Russia
- Шығарылым: Том 34, № 12 (2023)
- Беттер: 30-33
- Бөлім: Pharmacology
- URL: https://journals.rcsi.science/0236-3054/article/view/249760
- DOI: https://doi.org/10.29296/25877305-2023-12-06
- ID: 249760
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Тек жазылушылар үшін
Аннотация
The authors discuss the treatment of chronic heart failure (CHF) and present the results of our own study on the use of dapagliflozin in combination with standard therapy in patients with CHF. The comparison group consisted of patients receiving standard therapy with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-adrenoblockers and mineralocorticoid receptor antagonists.
Толық мәтін
##article.viewOnOriginalSite##Авторлар туралы
N. Zaporozhskaya
Rostov State Medical University, Ministry of Health of Russia
Хат алмасуға жауапты Автор.
Email: musurivskaya@mail.ru
ORCID iD: 0000-0002-6370-035X
Ресей, Rostov-on-Don
E. Kartashova
Rostov State Medical University, Ministry of Health of Russia
Email: musurivskaya@mail.ru
ORCID iD: 0000-0003-0912-2568
Candidate of Medical Sciences
Ресей, Rostov-on-DonE. Zheleznyak
Rostov State Medical University, Ministry of Health of Russia
Email: musurivskaya@mail.ru
ORCID iD: 0000-0002-5165-1044
Candidate of Medical Sciences
Ресей, Rostov-on-DonӘдебиет тізімі
- Kramer C.K., Zinman B. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. Annu Rev Med. 2019; 70: 323–34. doi: 10.1146/annurev-med-042017-094221.
- Wiviott S.D., Raz I., Bonaca M.P. et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018; 200: 83–9. doi: 10.1016/j.ahj.2018.01.012
- McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381 (21): 1995–2008. doi: 10.1056/NEJMoa1911303
- Dewan P., Jackson A., Lam C.S.P. et al. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. Eur J Heart Fail. 2020; 22 (5): 898–901. doi: 10.1002/ejhf.1776
- Solomon S.D., Vaduganathan M., Claggett B.L. et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020; 141 (5): 352–61. doi: 10.1161/CIRCULATIONAHA.119.044586
Қосымша файлдар
